JP Morgan Chase
ANTH

JP Morgan Chase’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

JP Morgan Chase’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-29,391
Closed -$9K – 5830
2018
Q1 		$9K Buy
+29,391
New +$43.9K ﹤0.01% 5190
2016
Q3 		– Sell
-266
Closed -$7K – 4990
2016
Q2 		$7K Buy
266
+229
+619% +$6.47K ﹤0.01% 4415
2016
Q1 		$1K Buy
+37
New +$1K ﹤0.01% 4609

Other funds holding ANTH

WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

JP Morgan Chase's ANTH Position: Q2 2018 in Review

JP Morgan Chase sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q2 2018, closing a stake of 29,391 shares — an estimated $9K sold.

JP Morgan Chase first reported a position in ANTH in Q1 2016 and held it in 3 quarters. The position peaked at $9K in Q1 2018. 5 funds tracked by Wall St. Rank hold ANTH as of Q2 2018.

  • JP Morgan Chase reported no remaining Anthera Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
  • JP Morgan Chase sold 29,391 Anthera Pharmaceuticals, Inc. shares in Q2 2018, an estimated $9K.
  • JP Morgan Chase first reported a position in Anthera Pharmaceuticals, Inc. in Q1 2016 and held it in 3 quarters.
  • JP Morgan Chase's Anthera Pharmaceuticals, Inc. position peaked at $9K in Q1 2018.
  • 5 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q2 2018.

Based on JP Morgan Chase's 13F filing for Q2 2018, filed 14 Aug 2018.